CA3036770A1 - Mousse pharmaceutique stable - Google Patents
Mousse pharmaceutique stable Download PDFInfo
- Publication number
- CA3036770A1 CA3036770A1 CA3036770A CA3036770A CA3036770A1 CA 3036770 A1 CA3036770 A1 CA 3036770A1 CA 3036770 A CA3036770 A CA 3036770A CA 3036770 A CA3036770 A CA 3036770A CA 3036770 A1 CA3036770 A1 CA 3036770A1
- Authority
- CA
- Canada
- Prior art keywords
- full
- peptone
- protein
- foam
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008255 pharmaceutical foam Substances 0.000 title claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 181
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 181
- 239000001888 Peptone Substances 0.000 claims abstract description 161
- 108010080698 Peptones Proteins 0.000 claims abstract description 161
- 235000019319 peptone Nutrition 0.000 claims abstract description 161
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 65
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000413 hydrolysate Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 235000018102 proteins Nutrition 0.000 claims description 179
- 239000006260 foam Substances 0.000 claims description 178
- 239000000243 solution Substances 0.000 claims description 76
- 108010010803 Gelatin Proteins 0.000 claims description 68
- 239000008273 gelatin Substances 0.000 claims description 68
- 229920000159 gelatin Polymers 0.000 claims description 68
- 235000019322 gelatine Nutrition 0.000 claims description 68
- 235000011852 gelatine desserts Nutrition 0.000 claims description 68
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 45
- 239000003531 protein hydrolysate Substances 0.000 claims description 45
- 238000005187 foaming Methods 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000190 Thrombin Proteins 0.000 claims description 25
- 229960004072 thrombin Drugs 0.000 claims description 25
- 239000005018 casein Substances 0.000 claims description 24
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 24
- 235000021240 caseins Nutrition 0.000 claims description 24
- 108010049003 Fibrinogen Proteins 0.000 claims description 22
- 102000008946 Fibrinogen Human genes 0.000 claims description 22
- 229940012952 fibrinogen Drugs 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910001868 water Inorganic materials 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108091005503 Glutamic proteases Proteins 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108091005501 Threonine proteases Proteins 0.000 claims description 4
- 102000035100 Threonine proteases Human genes 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 description 30
- 238000007906 compression Methods 0.000 description 29
- 230000006835 compression Effects 0.000 description 29
- 108010076119 Caseins Proteins 0.000 description 22
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 22
- 229940066779 peptones Drugs 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000006193 liquid solution Substances 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 238000005903 acid hydrolysis reaction Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 208000031737 Tissue Adhesions Diseases 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008258 liquid foam Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des compositions de mousse pharmaceutique comprenant une peptone, un hydrolysat peptidique ou une protéine hydrolysée par voie enzymatique préparée par hydrolyse enzymatique d'une protéine pleine longueur; des procédés de préparation et des utilisations de celles-ci.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394371P | 2016-09-14 | 2016-09-14 | |
| IL247810A IL247810A0 (en) | 2016-09-14 | 2016-09-14 | Stable pharmaceutical foam |
| US62/394,371 | 2016-09-14 | ||
| IL247810 | 2016-09-14 | ||
| PCT/IL2017/000007 WO2018051325A1 (fr) | 2016-09-14 | 2017-09-11 | Mousse pharmaceutique stable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036770A1 true CA3036770A1 (fr) | 2018-03-22 |
Family
ID=60022140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036770A Abandoned CA3036770A1 (fr) | 2016-09-14 | 2017-09-11 | Mousse pharmaceutique stable |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3512502A1 (fr) |
| JP (1) | JP7114597B2 (fr) |
| KR (1) | KR102656742B1 (fr) |
| CN (1) | CN109789091A (fr) |
| AU (1) | AU2017328480A1 (fr) |
| CA (1) | CA3036770A1 (fr) |
| IL (1) | IL265252B2 (fr) |
| MA (1) | MA46239A (fr) |
| WO (1) | WO2018051325A1 (fr) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2492458A (en) | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
| CH264752A (de) * | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Verfahren zur Herstellung von Trägern für Arzneimittel. |
| JPS5814813B2 (ja) * | 1976-11-09 | 1983-03-22 | 味の素株式会社 | 起泡剤及びその製造法 |
| US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
| WO2001005443A1 (fr) | 1999-07-21 | 2001-01-25 | Imedex Biomateriaux | Mousse proteique adhesive a usage chirurgical et/ou therapeutique |
| ATE258808T1 (de) | 2000-02-25 | 2004-02-15 | David Sierra | Schaumbildender wundverband |
| JP4113781B2 (ja) * | 2001-03-26 | 2008-07-09 | バイエル アクチェンゲゼルシャフト | 顕著な「ずり流動化特性」を示す溶融重合ポリカーボネート |
| US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
| US6749842B2 (en) * | 2002-01-24 | 2004-06-15 | Midwest Grain Products | Liquid foam builder containing hydrolyzed grain protein |
| WO2009023745A1 (fr) | 2007-08-14 | 2009-02-19 | The Regents Of The University Of California | Mousses mésocellulaires oxydes utilisées comme compositions hémostatiques et procédés d'utilisation |
| EP2227263A2 (fr) * | 2007-12-28 | 2010-09-15 | Kuros Biosurgery AG | Protéines hybrides du pdgf incorporées dans des mousses de fibrine |
| US8642831B2 (en) * | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| KR101541702B1 (ko) * | 2008-03-03 | 2015-08-04 | 옴릭스 바이오파머슈티컬스 리미티드 | 활성 성분을 포함하는 젤라틴 스펀지, 이의 제조 방법 및 용도 |
| US8512740B2 (en) | 2008-03-26 | 2013-08-20 | Baxter International Inc. | Fibrin foam and process for making |
| US8753670B2 (en) | 2008-03-26 | 2014-06-17 | Baxter International Inc. | Fibrin foam and process |
| US20110036133A1 (en) * | 2008-04-18 | 2011-02-17 | N. V. Organon | Purification of protein hydrolysate and the result and products |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US8778883B2 (en) | 2009-11-13 | 2014-07-15 | Industrial Technology Research Institute | Foamy biomaterial for biological tissue repair |
| RU2013155713A (ru) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
| US8680240B1 (en) * | 2012-11-01 | 2014-03-25 | George David Falus | Tissue sealant for use in non-compressible hemorrhage |
| ES2804534T3 (es) | 2012-12-07 | 2021-02-08 | Baxter Int | Espuma hemostática |
| CN105543315A (zh) * | 2015-12-16 | 2016-05-04 | 陕西科技大学 | 胶原蛋白类发泡剂、其复配改性发泡剂以及二者的制备方法 |
-
2017
- 2017-09-11 EP EP17780529.8A patent/EP3512502A1/fr not_active Withdrawn
- 2017-09-11 CA CA3036770A patent/CA3036770A1/fr not_active Abandoned
- 2017-09-11 MA MA046239A patent/MA46239A/fr unknown
- 2017-09-11 KR KR1020197010499A patent/KR102656742B1/ko active Active
- 2017-09-11 CN CN201780056569.1A patent/CN109789091A/zh active Pending
- 2017-09-11 WO PCT/IL2017/000007 patent/WO2018051325A1/fr not_active Ceased
- 2017-09-11 IL IL265252A patent/IL265252B2/en unknown
- 2017-09-11 AU AU2017328480A patent/AU2017328480A1/en not_active Abandoned
- 2017-09-11 JP JP2019536003A patent/JP7114597B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512502A1 (fr) | 2019-07-24 |
| IL265252A (en) | 2019-05-30 |
| JP2019526646A (ja) | 2019-09-19 |
| IL265252B2 (en) | 2023-11-01 |
| IL265252B1 (en) | 2023-07-01 |
| CN109789091A (zh) | 2019-05-21 |
| AU2017328480A1 (en) | 2019-03-14 |
| KR20190054110A (ko) | 2019-05-21 |
| KR102656742B1 (ko) | 2024-04-15 |
| JP7114597B2 (ja) | 2022-08-08 |
| WO2018051325A1 (fr) | 2018-03-22 |
| MA46239A (fr) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burke et al. | Thermal gelation and tissue adhesion of biomimetic hydrogels | |
| AU2017275577B2 (en) | Plasma-based films and methods for making and using the same | |
| AU2013353931B2 (en) | Hemostatic foam | |
| US9694101B2 (en) | Flowable collagen-based hemostat and methods of use | |
| US20050037960A1 (en) | Methods and compositions for sealing tissue leaks | |
| CA2889848A1 (fr) | Perfectionnements d'agent de scellement etanche de tissu destine a etre utilise dans une hemorragie non compressible | |
| EP3074055B1 (fr) | Tampon sec comprenant de la thrombine et de la pectine | |
| CN110801528A (zh) | 一种硬脊膜封合水凝胶及其制备方法与应用 | |
| US11938165B2 (en) | Stable pharmaceutical foam | |
| JP5889188B2 (ja) | 組織接着用シート製剤 | |
| CA3036770A1 (fr) | Mousse pharmaceutique stable | |
| AU2016261108B2 (en) | Haemostatic compositions | |
| CN113365652B (zh) | 止血用组合物及包含该组合物的容器 | |
| JP2017202033A (ja) | 多糖止血剤 | |
| US20240368222A1 (en) | Peptide having blood coagulation activity, and use thereof | |
| WO2013021066A1 (fr) | Composition sous la forme d'un film comprenant du fibrinogène et un activateur de fibrinogène et applications de celle-ci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220311 |
|
| FZDE | Discontinued |
Effective date: 20220311 |